Theravance Biopharma Inc TBPH 深 滬
已收盤 06-18 16:00:00 美东时间
16.58
-0.130
-0.78%
華盛通- 最 高16.85
- 今 開16.72
- 成交量 95.29万股
- 最 低 16.48
- 昨 收 16.71
- 總市值 8.55亿
- 52周最高 21.03
- 市盈率 靜 8.06
- 換手率 1.85%
- 52周最低 10.822
- 委 比 98.14%
- 總股本 5155.30万
- 歷史最高 43.44
- 量 比 2.92
- 振 幅 2.21%
- 歷史最低 6.10
- 每 手 1
- 風險率 2.77%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Theravance Biopharma Q1 EPS $(0.10) Misses $0.03 Estimate, Sales $17.699M Beat $17.200M Estimate
Theravance Biopharma (NASDAQ:TBPH) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $0.03 by 433.33 percent. This is a 62.96 percent increase over losses of $(0.27) per share
05-07 20:41
Summers Value Fund adds TBPH, exits ADMA among Q1 moves
The Summers Value Fund LP returned -2.7% net in Q1 2026, underperforming the Russell 2000 Index ETF, which returned 0.9%, and the Russell 2000 Value Index ETF, which returned 4.9%. According to its qu...
04-29 23:26
美股大行评级 | 高盛首予PayPay“买入”评级；神经分泌生物科学获花旗等多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从13美元升至20美元；韦德布什：维持FuboTV"跑赢大市"评级，目标价从3.5美元升至24美元
04-08 18:35
B. Riley Securities Maintains Neutral on Theravance Biopharma, Raises Price Target to $17
B. Riley Securities analyst Mayank Mamtani maintains Theravance Biopharma (NASDAQ:TBPH) with a Neutral and raises the price target from $14 to $17.
04-08 00:47
Theravance Secures Long-Term YUPELRI Patent Litigation Settlement
Theravance Biopharma ( ($TBPH) ) has shared an update. On March 27, 2026, Thera...
03-31 07:18
美股大行评级 | 瑞穗上调MongoDB至"跑赢大市"，目标价从290美元升至325美元；麦格理下调小鹏评级至"中性" 目标价从24美元降至19美元
今日重点评级关注：HC Wainwright & Co.：维持Perspective Therapeutics"买入"评级，目标价从12美元升至13美元；Litchfield Hills：维持Star Equity Holdings"买入"评级，目标价从21美元升至28美元
03-24 10:07
美股大行评级 | 小摩、瑞穗等下调阿里目标价最低至164美元；达登饭店、联邦快递、林肯教育服务、Planet Labs等获多家大行上调目标价
今日重点评级关注：瑞穗：维持RELMADA THERAPEUTICS"跑赢大市"评级，目标价从10美元升至19美元；奥本海默：维持Pelthos Therapeutics"跑赢大市"评级，目标价从60美元升至62美元
03-23 13:53
BTIG Reiterates Buy on Theravance Biopharma, Maintains $21 Price Target
BTIG analyst Julian Harrison reiterates Theravance Biopharma (NASDAQ:TBPH) with a Buy and maintains $21 price target.
03-20 18:20
Theravance Biopharma reports Q4 results
Theravance Biopharma press release (TBPH): Q4 net income was $61.0 million. Revenue of $45.9 million. Cash, cash equivalents and marketable securities totaled $326.5 million as of December 31, 2025. M...
03-20 02:54
Theravance Biopharma Q4 EPS $1.15 Beats $1.02 Estimate, Sales $45.891M Miss $50.793M Estimate
Theravance Biopharma (NASDAQ:TBPH) reported quarterly earnings of $1.15 per share which beat the analyst consensus estimate of $1.02 by 12.75 percent. This is a 2400 percent increase over losses of $(0.05) per share from
03-19 20:37
